Strategic acquisition status Sanofi’s planned acquisition of Dynavax indicates potential channel and distribution realignment opportunities, suggesting a need to engage Sanofi’s vaccine and adjuvant teams for collaboration on HEPLISAV-B and CpG 1018 related programs.

Commercial portfolio leverage Dynavax already markets HEPLISAV-B and CpG 1018; pos for partnerships or co‑marketing arrangements with vaccine developers and adjuvant customers seeking to license CpG 1018 or co‑develop new adjuvanted vaccines.

Clinical development momentum Positive topline data from the Z‑1018 shingles vaccine candidate and ongoing Phase 1/2 programs present opportunities to discuss strategic partnerships, licensing, or joint development with late-stage vaccine developers seeking proven adjuvant and vaccine platforms.

Industry engagement Dynavax participation in investor conferences and public disclosures indicates active business development outreach; use these events to initiate conversations around pipeline funding, collaboration on adjuvant technology, and potential co‑development deals.

Financial and market positioning Significant funding and a publicly traded history plus a current revenue base position Dynavax as a viable partner for midsize biotech buyers seeking vaccine manufacturing scale, regulatory expertise, and established commercialization capabilities.